Seasonal Allergic Rhinitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for seasonal allergic rhinitis. 7 active patents protecting 2 drugs from 2+ originators. First major cliff: 2027. Daily refresh.

2
Approved drugs
7
Active US patents
70/100
Avg vulnerability
—
Annual revenue covered

Originators in Seasonal Allergic Rhinitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Covis 4 patents Bayer 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating seasonal allergic rhinitis. Each bar = one year. Y-axis scaled to peak year (4 patents).

1
27
4
28
2
32

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Omnaris
CICLESONIDE
 Covis 4 80 — 2028-02-01
Tussionex Pennkinetic
CHLORPHENIRAMINE MALEATE
 Bayer 3 60 — 2027-02-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8371292 Omnaris method of use 80 2028-02-01
8371292 Omnaris method of use 80 2028-02-01
8371292 Omnaris method of use 80 2028-02-01
8371292 Omnaris method of use 80 2028-02-01
9066942 Tussionex Pennkinetic method of use 68 2032-01-03
7863287 Tussionex Pennkinetic formulation 65 2027-02-28
9107921 Tussionex Pennkinetic formulation 48 2032-01-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9107921 Tussionex Pennkinetic formulation 48 2032-01-03
7863287 Tussionex Pennkinetic formulation 65 2027-02-28
9066942 Tussionex Pennkinetic method of use 68 2032-01-03
8371292 Omnaris method of use 80 2028-02-01
8371292 Omnaris method of use 80 2028-02-01
8371292 Omnaris method of use 80 2028-02-01
8371292 Omnaris method of use 80 2028-02-01

Related